Cambridge Healthtech Institute’s 9th Annual
Bispecific Antibody Therapeutics
Combination Therapy & Engineering Multi-Specificity
January 23-24, 2020
Part of the Antibody Therapeutics pipeline
CHI’s Bispecific Antibody Therapeutics conference explores the challenges of engineering multi-specificity to achieve more effective therapies that bind to at least two targets simultaneously. The conference examines how these molecules are used to fight a wide array of diseases, as well as in combination therapy for enhanced effects in the fight against cancer. Along with increased efficacy, Bispecific Antibody Therapeutics can also optimize expenses by reducing the cost of development and clinical trials. Case studies highlight novel engineering approaches and platform constructs that improve safety, stability, enhanced targeting, and manufacturability.
KEYNOTE PRESENTATION: The Landscape of Multi-Specific Antibodies
Partha S. Chowdhury, PhD, Senior Director and Head, Antibody Discovery, Sanofi Genzyme
Building Blocks for Bispecific and Trispecific Antibodies
Stephen Demarest, PhD, Senior Research Fellow, Protein Biosciences, Eli Lilly & Co.
Maximizing Therapeutic Potential of Bispecific Antibodies and Cytokines by Affinity and Avidity Engineering
David E. Szymkowski, PhD, Vice President, Cell Biology, Xencor, Inc.
Development of NM21-1480, A Trispecific Anti-PD-L1x4-1BBxhSA Antibody Fragment
Sebastian Meyer, PhD, Chief Operating Officer, Numab Therapeutics AG
T CELL ENGAGING BISPECIFICS TO FIGHT CANCER
Advancing a Novel T Cell Engaging Bispecific Antibody that Induces Lysis of Small Cell Lung Cancer Cells In Vitro and Shows Potent T Cell Re-Directed Anti-Tumor Activity In Vivo
Justin Scheer, PhD, Director, Protein and Antibody Engineering, Boehringer Ingelheim
Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3-Bispecifics and CAR T Cells
David J. DiLillo, PhD, Senior Staff Scientist, Immuno-Oncology, Regeneron Pharmaceuticals
HARNESSING THE IMMUNE SYSTEM
Modulating the Immune System with Multi-Specific Antibodies in Cancer
Nathan Trinklein, PhD, Chief Technology Officer, TeneoBio, Inc.
Engineered Multispecific Antibodies for Targeted Inhibition of Cancer Metastasis
Jamie B. Spangler, PhD, Assistant Professor, Biomedical Engineering and Chemical & Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University
ATOR-1015, A Bispecific CTLA-4 x OX40 Antibody, Induces Anti-Tumor Effects Through Tumor-Directed Immune Activation
Christina Furebring, PhD, Senior Vice President, Preclinical Development, Alligator Bioscience
* The program is subject to change without notice, due to unforeseen reason.
2020 Conferences & Training Seminars